The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  T. Nozue,et al.  Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia , 2015, Lipids in Health and Disease.

[3]  Simon G Thompson,et al.  Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. , 2014, Annals of internal medicine.

[4]  I. Komuro,et al.  Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. , 2014, The American journal of cardiology.

[5]  Hisashi Adachi,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[6]  Yongsoon Park,et al.  Erythrocyte n-3 Polyunsaturated Fatty Acids and the Risk of Type 2 Diabetes in Koreans: A Case-Control Study , 2013, Annals of Nutrition and Metabolism.

[7]  T. Ninomiya,et al.  Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. , 2013, Atherosclerosis.

[8]  J. Hiltunen,et al.  Dietary intake of n-3 long-chain polyunsaturated fatty acids and risk of myocardial infarction in coronary artery disease patients with or without diabetes mellitus: a prospective cohort study , 2013, BMC Medicine.

[9]  A. Santarelli,et al.  Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. , 2013, Chest.

[10]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[11]  I. Komuro,et al.  Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocardial infarction. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[12]  E. Ntzani,et al.  Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. , 2012, JAMA.

[13]  J. Geleijnse,et al.  Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. , 2012, European heart journal.

[14]  M. Nobuyoshi,et al.  Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[15]  M. Hayashi,et al.  Association of Plasma Omega-3 to Omega-6 Polyunsaturated Fatty Acid Ratio with Complexity of Coronary Artery Lesion , 2012 .

[16]  M. Hayashi,et al.  Association of plasma ω-3 to ω-6 polyunsaturated fatty acid ratio with complexity of coronary artery lesion. , 2012, Internal medicine.

[17]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[18]  T. Murohara,et al.  Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. , 2011, Atherosclerosis.

[19]  J. Geleijnse,et al.  n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.

[20]  P. Calder,et al.  Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. , 2010, Atherosclerosis.

[21]  K. Fukao,et al.  Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. , 2010, Journal of atherosclerosis and thrombosis.

[22]  M. Rizzo,et al.  An update on the role of markers of inflammation in atherosclerosis. , 2010, Journal of atherosclerosis and thrombosis.

[23]  Y. Jang,et al.  Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction--data from Infarction Prognosis Study (IPS) Registry. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[24]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[25]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[26]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  Y. Matsuzawa,et al.  Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[28]  F. Palm,et al.  Diabetes, oxidative stress, nitric oxide and mitochondria function. , 2009, Current diabetes reviews.

[29]  Peter Libby,et al.  Inflammation in Atherosclerosis : From Vascular Biology to Biomarker Discovery and Risk Prediction , 2007 .

[30]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[31]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[32]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[33]  C. Serhan.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[34]  E. Grossi.  BMC Cardiovascular Disorders , 2007 .

[35]  P. Calder,et al.  n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. , 2006, The American journal of clinical nutrition.

[36]  L. Tavazzi,et al.  Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial , 2005, The Journal of Membrane Biology.

[37]  R. Mackey,et al.  Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[38]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[39]  H. Kolb,et al.  Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4 , 1994, Diabetologia.

[40]  D. Mozaffarian,et al.  n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. , 2003, The American journal of clinical nutrition.

[41]  J. van de Voorde,et al.  Endothelial dysfunction in diabetes , 2000, British journal of pharmacology.

[42]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[43]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[44]  K. Lee,et al.  Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. , 1998, Circulation.

[45]  V. Fuster,et al.  Unstable angina: outcome according to clinical presentation. , 1992, Journal of the American College of Cardiology.

[46]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.